Organon & Co. Stock News

Organon (OGN) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.

CALGARY, Alberta--(BUSINESS WIRE)--Matt Sjogren, President of CUPE 37 (City of Calgary outside workers) issued the following statement after employees rejected a contract settlement offer. Last night,

SHANGHAI, China & JERSEY CITY, N.J.--(BUSINESS WIRE)---- $OGN #denosumabbiosimilar--European Medicines Agency validates Organon and Henlius marketing authorization filings for Prolia and Xgeva (denosu

VITL, SFM, RCL, AEM and OGN are five stocks with explosive relative price strength.

Natixis Advisors L.P. reduced its stake in shares of Organon & Co. (NYSE:OGN – Free Report) by 4.5% in the 4th quarter, according to its most recent Form 13F filing with the Securities and

Since it's becoming difficult to downplay the idea of stagflation, investors should place their bets on ultra-safe stocks such as Western Union (WU), Frontline (FRO) and Organon (OGN).

Organon (OGN) shares have started gaining and might continue moving higher in the near term, as indicated by solid earnings estimate revisions.

OGN, ODP and ASC made it to the Zacks Rank #1 (Strong Buy) value stocks list on May 13, 2024.

Organon, Pfizer, and Bristol Myers all offer yields above 5% and can  compete with most Treasuries, but only Organon is up YTD. Spinoffs often struggle in their initial years, but Organon's partial r

JERSEY CITY, N.J.--(BUSINESS WIRE)--Organon (NYSE: OGN) (“Organon”), a global healthcare company with a focus on women's health, announced today that it, together with Organon Foreign Debt Co-Issu

OGN has underperformed its healthcare peers and the benchmark over the past year, but this could change going forward. The company's dominant women's health product- Nexplanon is looking at double-dig

JERSEY CITY, N.J.--(BUSINESS WIRE)--Organon (NYSE: OGN) (“Organon”), a global healthcare company with a focus on women's health, announced today that it, together with Organon Foreign Debt Co-Issu

Organon (OGN) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

Organon & Co. (NYSE:OGN ) Q1 2024 Earnings Conference Call May 2, 2024 8:30 AM ET Company Participants Jennifer Halchak - Vice President, Investor Relations Kevin Ali - Chief Executive Officer Matt Wa

Organon (OGN) came out with quarterly earnings of $1.22 per share, beating the Zacks Consensus Estimate of $0.97 per share. This compares to earnings of $1.08 per share a year ago.